Tuvirumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| verifiedrevid = 470618986

| image =

| type = mab

| mab_type =

| source = u

| target = hepatitis B virus

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 138660-97-6

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII = 31Z0AB5WNC

| chemical_formula =

| molecular_weight =

}}

Tuvirumab is a human monoclonal antibody for the treatment of patients with chronic hepatitis B. It has undergone Phase I clinical trials in 2001.{{cite journal | vauthors = Heijtink RA, van Nunen AB, van Bergen P, Ostberg L, Osterhaus AD, de Man RA | title = Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes | journal = Journal of Medical Virology | volume = 64 | issue = 4 | pages = 427–34 | date = August 2001 | pmid = 11468726 | doi = 10.1002/jmv.1068 | s2cid = 28825387 }}{{cite journal | vauthors = van Nunen AB, Baumann M, Manns MP, Reichen J, Spengler U, Marschner JP, de Man RA | title = Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients | journal = Liver | volume = 21 | issue = 3 | pages = 207–12 | date = June 2001 | pmid = 11422784 | doi = 10.1034/j.1600-0676.2001.021003207.x | url = http://repub.eur.nl/pub/66667 | hdl = 1765/66667 | hdl-access = free }}